Laurel A. Menapace/LinkedIn
Aug 2, 2026, 09:04
Laurel A. Menapace: Investing in the Next Generation of Hematology Leaders
Laurel A. Menapace, Former Senior Clinical Research Director of Rare Blood Disorders, Fitusiran Development Program at Sanofi, shared a post on LinkedIn:
“Thoroughly enjoyed participating in ISTH’s ECC Networking with Industry Session.
Some of the best career advice I’ve received has come from people willing to share their experiences openly.
I’m grateful for the opportunity to pay that forward and discuss career paths, clinical development, industry partnerships, and the many ways we can continue advancing therapies for patients.
Building the future of hematology requires more than great science—it requires investing in the people who will lead it.”
Stay updated with Hemostasis Today.
-
Sep 15, 2026, 02:59Caterina Casari: Curious about How Gene Editing is Revolutionizing Our Field?
-
Sep 15, 2026, 02:53Alejandro González Veliz: Can Lifestyle Changes Actually Reverse Atherosclerosis?
-
Sep 15, 2026, 02:08Eugenia Gianos: ACC CVPrevention Council’s New Statin Resources
-
Sep 15, 2026, 01:58Shinya Goto: Country Specific Randomized Trial Show the Merit of DOAC in Intermediate Risk of A
-
Sep 15, 2026, 01:37Lesley Van Wyk: Exploring Sickle Cell Disease – The HbS Story
-
Sep 15, 2026, 01:31Luca Seffin: To the Science, the People, and the Journey – Thank You SR-Tiget
-
Sep 14, 2026, 23:49Heghine Khachatryan: New evidance – Antiphospholipid Antibodies and Ischemic Stroke
-
Sep 14, 2026, 23:42Eman M. Elsabbagh: Successful HCT Does Not End at Engraftment
-
Sep 14, 2026, 23:31Antonis Kattamis: Proud to Be Part of this Endeavour and Senior Author of the Pivotal Trial